Jermaine Thomas

USPTO Granted Patents = 21 (Patent Applications = 5)

CIPO Patents = 3

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 10.0

ph-index = 4

Forward Citations = 73(Granted Patents)

Location History:

Chelsea, MA (US) (2012 - 2021)
Cambridge, MA (US) (2019 - 2022)

Company Filing History:

Sunesis Pharmaceuticals, Inc.

Millenium Pharmaceuticals, Inc.

patents

6. 1 out of 850

Millennium Pharmaceuticals Limited

patents

where one patent can have more than one assignee

Years Active: 2012-2022

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11427561 - IRAK4 inhibiting agents (2022-08-30),

2. 10894040 - S1P modulating agents (2021-01-19),

3. 10577367 - IRAK4 inhibiting agents (2020-03-03),

4. 10406144 - SIP modulating agents (2019-09-10),

5. 10246456 - IRAK4 inhibiting agents (2019-04-02),

6. 10166250 - Bicyclic aryl sphingosine 1-phosphate analogs (2019-01-01),

7. 10081646 - Heterobicyclic sphingosine 1-phosphate analogs (2018-09-25),

8. 10034869 - S1P modulating agents (2018-07-31),

9. 10030016 - Heterocyclic compounds useful as PDK1 inhibitors (2018-07-24),

10. 9827258 - Bicyclic aryl sphingosine 1-phosphate analogs (2017-11-28),

11. 9808449 - S1P modulating agents (2017-11-07),

12. 9708353 - Heterobicyclic sphingosine 1-phosphate analogs (2017-07-18),

13. 9572824 - Bicyclic aryl sphingosine 1-phosphate analogs (2017-02-21),

14. 9546165 - Heterocyclic compounds useful as PDK1 inhibitors (2017-01-17),

15. 9340527 - S1P modulating agents (2016-05-17),

Title: Jermaine Thomas: A Pioneering Inventor from Chelsea, MA

Introduction

Jermaine Thomas is an accomplished inventor based in Chelsea, MA, holding an impressive portfolio of 21 patents. His work has significantly contributed to advancements in biomedical research, particularly in the fields of inflammatory diseases, autoimmune disorders, and cancer therapies.

Latest Patents

Among his latest innovations are two notable patents. The first is for IRAK4 inhibiting agents, which include compounds of Formula I or their pharmaceutically acceptable salts. These compounds are designed to inhibit IRAK-4, making them effective for treating various medical conditions such as inflammatory and autoimmune diseases, cancer, cardiovascular diseases, central nervous system disorders, skin diseases, ophthalmic diseases, and bone diseases. The second innovation is related to S1P modulating agents. This patent presents compounds of formula (I) or (II) and outlines their use in modulating the activity of S1P receptors. Additionally, it describes a pharmaceutical composition comprising these compounds and a pharmaceutically acceptable excipient or carrier.

Career Highlights

Jermaine has worked with prominent companies in the biotechnology sector, notably Biogen MA Inc. and Biogen Idec MA Inc. His experiences in these organizations have allowed him to collaborate with some of the brightest minds in the industry.

Collaborations

Throughout his professional journey, Jermaine has had the opportunity to work alongside talented individuals such as Kevin Guckian and Gnanasambandam Kumaravel. Their collaborations have undoubtedly enriched the development of innovative solutions in the complex realm of medical therapies.

Conclusion

Jermaine Thomas exemplifies the spirit of innovation and dedication to improving healthcare outcomes. With a robust record of patents and collaborations, he continues to make a significant impact in the field of biomedical technology, paving the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.